Award
NIH Reporter #75N93023C00042-P00004-9999-1
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
Recipient
INIMMUNE CORPORATION
Award Amount
$1,648,211.00
Ceiling
$1,648,211.00
Awarded
September 30, 2023
Identifier
75N93023C00042-P00004-9999-1
Inimmune Corporation received funding to develop and scale-up a synthetic AS01-like adjuvant system for influenza vaccines, aiming to enhance immune response and advance to IND submission.
Description
Inimmune is developing a second generation synthetic AS01-like adjuvant system (termed SAS), by partnering our novel fully synthetic TLR4 agonist INI-2002, with a semi-synthetic saponin for use in vaccines. Pre-clinically, SAS has demonstrated excellent antibody and T-cell immune responses when paired with a split flu antigen. This versatile vaccine adjuvant is expected to provide a significant enhancement to the immune response to both viral and bacterial vaccines while exhibiting a favorable safety profile. Under this contract, Inimmune, in collaboration with its subcontracting partners, will optimize, scale-up, and produce cGMP SAS in an effort to advance it to an IND submission.